Get the Stockscreener App
0.9215
14.15%
0.1228
Allarity Therapeutics Inc stock is traded at $0.9215, with a volume of 8.00M.
It is up +14.15% in the last 24 hours and down -18.60% over the past month.
Allarity Therapeutics Inc is a clinical-stage, precision medicine company. The company is actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Its Drug Response Predictor (DRP) technology refines patient selection and improves clinical outcomes. Its pipeline product includes Dovitinib, Stenoparib, Ixempra, and other formulations.
See More
Previous Close:
$0.7987
Open:
$0.791
24h Volume:
8.00M
Relative Volume:
4.24
Market Cap:
$3.92M
Revenue:
-
Net Income/Loss:
$-11.90M
P/E Ratio:
-0.00447
EPS:
-206.0125
Net Cash Flow:
$-12.75M
1W Performance:
+11.17%
1M Performance:
-18.60%
6M Performance:
+444.30%
1Y Performance:
-88.91%
1-Day Range:
$0.791
$0.97
1-Week Range:
$0.6775
$0.97
52-Week Range:
$0.1131
$8.58
Allarity Therapeutics Inc Stock (ALLR) Company Profile
Name
Allarity Therapeutics Inc
Sector
Industry
Phone
401-426-4664
Address
24 SCHOOL ST., 2ND FLOOR, BOSTON
Compare ALLR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALLR
Allarity Therapeutics Inc
|
0.915 | 3.92M | 0 | -11.90M | -12.75M | -206.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.18 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
690.05 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
636.58 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
113.23 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Allarity Therapeutics Inc Stock (ALLR) Latest News
Allarity Therapeutics Announces Board Authorization Of $5 Million Share Repurchase Program - TradingView
ALLR STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Allarity Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Allarity Therapeutics Announces Dismissal of Securities Class Action Lawsuit - GlobeNewswire
Allarity Therapeutics stock hits 52-week low at $0.87 By Investing.com - Investing.com Nigeria
Allarity Therapeutics stock hits 52-week low at $0.87 - Investing.com
Allarity Therapeutics to Begin Enrollment for New Phase 2 - GlobeNewswire
Can This New Ovarian Cancer Drug Challenge the $9B PARP Market? Complete Response Data Emerges - StockTitan
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics - ACCESS Newswire
ALLR ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Allarity Therapeutics, Inc. - ACCESS Newswire
Allarity Therapeutics, Inc. (ALLR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - Markets Insider
Bronstein, Gewirtz & Grossman, LLC Is Investigating Allarity Therapeutics, Inc. (ALLR) And Encourages Shareholders to Connect - Markets Insider
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Allarity Therapeutics, Inc. (ALLR) And Encourages Shareholders to Reach Out - Markets Insider
Allarity Therapeutics Inc (ALLR) is looking forward to a strong quarter - SETE News
Can Allarity Therapeutics Inc (ALLR) meet market expectations this quarter? - US Post News
Bronstein, Gewirtz & Grossman, LLC Encourages Allarity Therapeutics, Inc. (ALLR) Stockholders to Inquire about Securities Investigation - Markets Insider
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Allarity Therapeutics, Inc. (ALLR) and Encourages Investors to Learn More About the Investigation - Markets Insider
Allarity Therapeutics advances ovarian cancer drug trial - MSN
Allarity Therapeutics (NASDAQ:ALLR) and Xilio Therapeutics (NASDAQ:XLO) Financial Contrast - Defense World
Allarity Therapeutics Inc (NASDAQ: ALLR) Gain Of 13.46% Compared To 52-Week Low; YTD Fall -11.11% – What Should You Do Now? – Marketing Sentinel - Marketing Sentinel
Bronstein, Gewirtz & Grossman, LLC Is Investigating Allarity Therapeutics, Inc. (ALLR) And Encourages Investors to Connect - Markets Insider
Allarity Therapeutics Announces Expansion of Phase 2 - GlobeNewswire
Breakthrough Ovarian Cancer Drug Shows 14-Month Durability: Allarity Advances Clinical Trial - StockTitan
Allarity Therapeutics Inc’s Shares Reel: -24.64% Quarterly Revenue Decline Amid 4.68M Market Cap - The InvestChronicle
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Allarity Therapeutics, Inc. (ALLR) And Encourages Investors to Reach Out - Markets Insider
ALLR’s earnings forecast for the current quarter - US Post News
Ratios Reveal: Breaking Down Allarity Therapeutics Inc (ALLR)’s Financial Health - The Dwinnex
Allarity Therapeutics Reaches Settlement in Principle with SEC - Defense World
Bronstein, Gewirtz & Grossman, LLC Is Investigating Allarity Therapeutics, Inc. (ALLR) And Encourages Stockholders to Connect - Markets Insider
Allarity Therapeutics Announces Filing of Form 8-K Regarding Settlement Agreement in Principle with SEC - GlobeNewswire
Allarity's Stenoparib Shows 14-Month Patient Response as Company Nears SEC Resolution - StockTitan
2025-01-29 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Allarity Therapeutics, Inc. (ALLR) And Encourages Investors to Connect | NDAQ:ALLR | Press Release - Stockhouse Publishing
ALLR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Allarity Therapeutics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
When Does Allarity Therapeutics Inc (ALLR) Become A Good Investment? - Marketing Sentinel
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Allarity Therapeutics, Inc. (ALLR) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
2025-01-26 | Bronstein, Gewirtz & Grossman, LLC Encourages Allarity Therapeutics, Inc. (ALLR) Stockholders to Inquire about Securities Investigation | NDAQ:ALLR | Press Release - Stockhouse Publishing
ALLR STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Allarity Therapeutics, Inc. and Encourages Shareholders to Contact the Firm! - ACCESS Newswire
ALLR STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Allarity Therapeutics, Inc. and Encourages Investors to Contact the Firm! - ACCESS Newswire
No Stopping Allarity Therapeutics Inc (NASDAQ: ALLR)’s Stock Surged? - Stocks Register
2025-01-19 | Allarity Therapeutics, Inc. (ALLR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:ALLR | Press Release - Stockhouse Publishing
2025-01-15 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Allarity Therapeutics, Inc. (ALLR) And Encourages Stockholders to Reach Out | NDAQ:ALLR | Press Release - Stockhouse Publishing
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on B - GuruFocus.com
Allarity Therapeutics, Inc. (ALLR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - AccessWire
2025-01-08 | Allarity Therapeutics, Inc. (ALLR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | NDAQ:ALLR | Press Release - Stockhouse Publishing
2025-01-02 | Allarity Therapeutics, Inc. (ALLR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:ALLR | Press Release - Stockhouse Publishing
Allarity Therapeutics, Inc. (ALLR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - AccessWire
2024-12-30 | Bronstein, Gewirtz & Grossman, LLC Encourages Allarity Therapeutics, Inc. (ALLR) Investors to Inquire about Securities Investigation | NDAQ:ALLR | Press Release - Stockhouse Publishing
Cancer, GI-focused Onconic shares take off after ₩20B IPO - BioWorld Online
ALLR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Allarity Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - The Eastern Progress Online
ALLARITY THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) - Marketscreener.com
Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Allarity Therapeutics, Inc. (NASDAQ: ALLR) for potential violations of federal securities laws - The Eastern Progress Online
ALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud Lawsuit - Kilgore News Herald
Allarity Therapeutics Inc Stock (ALLR) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.93%
1.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):